Aridis Pharmaceuticals Inc
NASDAQ:ARDS
Aridis Pharmaceuticals Inc
NASDAQ:ARDS
Price:
0.065 USD
Market Closed
Updated:
Apr 28, 2024
Aridis Pharmaceuticals Inc
Cash from Financing Activities
|
Aridis Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Aridis Pharmaceuticals Inc
NASDAQ:ARDS
|
Cash from Financing Activities
$14.8m
|
CAGR 3-Years
44%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Aridis Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
14.8m
USD
14.8m
USD
Based on the financial report for Dec 31, 2022, Aridis Pharmaceuticals Inc's Cash from Financing Activities amounts to 14.8m USD.
What is Aridis Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-7%
-7%
Over the last year, the Cash from Financing Activities growth was -57%. The average annual Cash from Financing Activities growth rates for Aridis Pharmaceuticals Inc have been 44% over the past three years , -7% over the past five years .
You don't have any saved screeners yet
